ReP USP - Resultado da busca

Artigo de periodico
Treatment outcomes for Hodgkin lymphoma: first report from the Brazilian Prospective Registry (2018)
Biasoli, Irene; Castro, Nelson; Delamain, Marcia; Silveira, Talita; Farley, James; Simões, Belinda Pinto; Solza, Cristiana; Praxedes, Monica; Baiocchi, Otávio; Gaiolla, Rafael; Franceschi, Fernanda; Sola, Caroline Bonamin; Boquimpani, Carla; Clementino, Nelma; Perini, Guilherme; Pagnano, Kátia; Steffenello, Giovanna; Tabacof, Jacques; Colli, Gilberto de Freitas; Soares, Andrea; Souza, Carmino de; Chiattone, Carlos Sérgio; Milito, Cristiane; Morais, José Carlos; Spector, Nelson
Source: Hematological Oncology. Unidade: FMRP
Subjects: LINFOMA, LINFONODOS, NEOPLASIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BIASOLI, Irene et al. Treatment outcomes for Hodgkin lymphoma: first report from the Brazilian Prospective Registry. Hematological Oncology, v. 36, n. 1, p. 189-195, 2018Tradução . . Disponível em: https://doi.org/10.1002/hon.2450. Acesso em: 01 nov. 2024.
APA
Biasoli, I., Castro, N., Delamain, M., Silveira, T., Farley, J., Simões, B. P., et al. (2018). Treatment outcomes for Hodgkin lymphoma: first report from the Brazilian Prospective Registry. Hematological Oncology, 36( 1), 189-195. doi:10.1002/hon.2450
NLM
Biasoli I, Castro N, Delamain M, Silveira T, Farley J, Simões BP, Solza C, Praxedes M, Baiocchi O, Gaiolla R, Franceschi F, Sola CB, Boquimpani C, Clementino N, Perini G, Pagnano K, Steffenello G, Tabacof J, Colli G de F, Soares A, Souza C de, Chiattone CS, Milito C, Morais JC, Spector N. Treatment outcomes for Hodgkin lymphoma: first report from the Brazilian Prospective Registry [Internet]. Hematological Oncology. 2018 ; 36( 1): 189-195.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1002/hon.2450
Vancouver
Biasoli I, Castro N, Delamain M, Silveira T, Farley J, Simões BP, Solza C, Praxedes M, Baiocchi O, Gaiolla R, Franceschi F, Sola CB, Boquimpani C, Clementino N, Perini G, Pagnano K, Steffenello G, Tabacof J, Colli G de F, Soares A, Souza C de, Chiattone CS, Milito C, Morais JC, Spector N. Treatment outcomes for Hodgkin lymphoma: first report from the Brazilian Prospective Registry [Internet]. Hematological Oncology. 2018 ; 36( 1): 189-195.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1002/hon.2450
Trabalho de evento-resumo periodico
Stathmin 1 é altamente expressa em leucemia promielocítica aguda e a dinâmica dos microtúbulos é um alvo potencial para células PML-RAR resistentes ao atra (2017)
Machado Neto, João Agostinho ; Silva, Juan Luiz Coelho da; Lucena-Araújo, Antonio Roberto; Scheucher, Priscila Santos; Melo, Raul Antonio Morais; Bittencourt, Rosane; Pasquini, Ricardo; Pagnano, Katia; Fagundes, Evandro Maranhão; Chauffaille, Maria de Lourdes Lopes Ferrari; Chiattone, Carlos Sérgio; Rego, Eduardo Magalhães; Traina, Fabiola
Source: Revista Brasileira de Hematologia e Hemoterapia. Conference titles: Congresso Brasileiro de Hematologia, Hemoterapia e Terapia Celular (HEMO 2017). Unidades: ICB, FMRP
Subjects: LEUCEMIA, FENÓTIPOS, ONCOPROTEÍNAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO NETO, João Agostinho et al. Stathmin 1 é altamente expressa em leucemia promielocítica aguda e a dinâmica dos microtúbulos é um alvo potencial para células PML-RAR resistentes ao atra. Revista Brasileira de Hematologia e Hemoterapia. Rio de Janeiro: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: https://www.abhheventos.com.br/hemo2017/wp-content/uploads/2014/01/SUPLEMENTO-HEMO-2017.pdf. Acesso em: 01 nov. 2024. , 2017
APA
Machado Neto, J. A., Silva, J. L. C. da, Lucena-Araújo, A. R., Scheucher, P. S., Melo, R. A. M., Bittencourt, R., et al. (2017). Stathmin 1 é altamente expressa em leucemia promielocítica aguda e a dinâmica dos microtúbulos é um alvo potencial para células PML-RAR resistentes ao atra. Revista Brasileira de Hematologia e Hemoterapia. Rio de Janeiro: Instituto de Ciências Biomédicas, Universidade de São Paulo. Recuperado de https://www.abhheventos.com.br/hemo2017/wp-content/uploads/2014/01/SUPLEMENTO-HEMO-2017.pdf
NLM
Machado Neto JA, Silva JLC da, Lucena-Araújo AR, Scheucher PS, Melo RAM, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille M de LLF, Chiattone CS, Rego EM, Traina F. Stathmin 1 é altamente expressa em leucemia promielocítica aguda e a dinâmica dos microtúbulos é um alvo potencial para células PML-RAR resistentes ao atra [Internet]. Revista Brasileira de Hematologia e Hemoterapia. 2017 ; 39 S123-S124.[citado 2024 nov. 01 ] Available from: https://www.abhheventos.com.br/hemo2017/wp-content/uploads/2014/01/SUPLEMENTO-HEMO-2017.pdf
Vancouver
Machado Neto JA, Silva JLC da, Lucena-Araújo AR, Scheucher PS, Melo RAM, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille M de LLF, Chiattone CS, Rego EM, Traina F. Stathmin 1 é altamente expressa em leucemia promielocítica aguda e a dinâmica dos microtúbulos é um alvo potencial para células PML-RAR resistentes ao atra [Internet]. Revista Brasileira de Hematologia e Hemoterapia. 2017 ; 39 S123-S124.[citado 2024 nov. 01 ] Available from: https://www.abhheventos.com.br/hemo2017/wp-content/uploads/2014/01/SUPLEMENTO-HEMO-2017.pdf
Artigo de periodico
Relationship between SLCO1B(3) and ABCA(3) polymorphisms and imatinib response in chronic myeloid leukemia patients (2015)
Lima, Luciene Terezina de; Bueno, Carolina Tosin; Vivona, Douglas; Hirata, Rosario Dominguez Crespo ; Hirata, Mario Hiroyuki ; Hungria, Vania Tietsche de Moraes; Chiattone, Carlos Sérgio; Zanichelli, Maria Aparecida; Chauffaille, Maria de Lourdes Lopes Ferrari; Guerra-Shinohara, Elvira Maria
Source: Hematology. Unidade: FCF
Subjects: LEUCEMIA MIELOIDE, FARMACOGENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Luciene Terezina de et al. Relationship between SLCO1B(3) and ABCA(3) polymorphisms and imatinib response in chronic myeloid leukemia patients. Hematology, v. 20, n. 3, p. 137-142, 2015Tradução . . Disponível em: https://doi.org/10.1179/1607845414Y.0000000181. Acesso em: 01 nov. 2024.
APA
Lima, L. T. de, Bueno, C. T., Vivona, D., Hirata, R. D. C., Hirata, M. H., Hungria, V. T. de M., et al. (2015). Relationship between SLCO1B(3) and ABCA(3) polymorphisms and imatinib response in chronic myeloid leukemia patients. Hematology, 20( 3), 137-142. doi:10.1179/1607845414Y.0000000181
NLM
Lima LT de, Bueno CT, Vivona D, Hirata RDC, Hirata MH, Hungria VT de M, Chiattone CS, Zanichelli MA, Chauffaille M de LLF, Guerra-Shinohara EM. Relationship between SLCO1B(3) and ABCA(3) polymorphisms and imatinib response in chronic myeloid leukemia patients [Internet]. Hematology. 2015 ; 20( 3): 137-142.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1179/1607845414Y.0000000181
Vancouver
Lima LT de, Bueno CT, Vivona D, Hirata RDC, Hirata MH, Hungria VT de M, Chiattone CS, Zanichelli MA, Chauffaille M de LLF, Guerra-Shinohara EM. Relationship between SLCO1B(3) and ABCA(3) polymorphisms and imatinib response in chronic myeloid leukemia patients [Internet]. Hematology. 2015 ; 20( 3): 137-142.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1179/1607845414Y.0000000181
Artigo de periodico
ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib (2014)
Vivona, Douglas; Lima, Luciene Terezin; Rodrigues, Alice Cristina ; Bueno, Carolina Tosin; Alcantara, Greyce Kelly Steinhorst; Barros, Luiza Saldanha Ribeiro; Hungria, Vania Tietsche de Moraes; Chiattone, Carlos Sérgio; Chauffaille, Maria de Lourdes Lopes Ferrari; Guerra-Shinohara, Elvira Maria
Source: Oncology Letters. Unidades: ICB, FCF
Subjects: LEUCEMIA MIELOIDE, POLIMORFISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIVONA, Douglas et al. ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib. Oncology Letters, v. 7, n. 4, p. 1313-1319, 2014Tradução . . Disponível em: https://doi.org/10.3892/ol.2014.1857. Acesso em: 01 nov. 2024.
APA
Vivona, D., Lima, L. T., Rodrigues, A. C., Bueno, C. T., Alcantara, G. K. S., Barros, L. S. R., et al. (2014). ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib. Oncology Letters, 7( 4), 1313-1319. doi:10.3892/ol.2014.1857
NLM
Vivona D, Lima LT, Rodrigues AC, Bueno CT, Alcantara GKS, Barros LSR, Hungria VT de M, Chiattone CS, Chauffaille M de LLF, Guerra-Shinohara EM. ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib [Internet]. Oncology Letters. 2014 ; 7( 4): 1313-1319.[citado 2024 nov. 01 ] Available from: https://doi.org/10.3892/ol.2014.1857
Vancouver
Vivona D, Lima LT, Rodrigues AC, Bueno CT, Alcantara GKS, Barros LSR, Hungria VT de M, Chiattone CS, Chauffaille M de LLF, Guerra-Shinohara EM. ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib [Internet]. Oncology Letters. 2014 ; 7( 4): 1313-1319.[citado 2024 nov. 01 ] Available from: https://doi.org/10.3892/ol.2014.1857
Artigo de periodico
Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia (2014)
Lima, Luciene Terezinha de; Vivona, Douglas; Bueno, Carolina Tosin; Hirata, Rosario Dominguez Crespo ; Hirata, Mario Hiroyuki ; Luchessi, André Ducati; Castro, Fabíola Attié de; Chauffaille, Maria de Lourdes L. F; Zanichelli, Maria Aparecida; Chiattone, Carlos Sérgio; Hungria, Vania Tietsche de Moraes; Guerra-Shinohara, Elvira Maria
Source: Medical Oncology. Unidades: FCF, FCFRP
Subjects: LEUCEMIA MIELOIDE, POLIMORFISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Luciene Terezinha de et al. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. Medical Oncology, v. 31, p. 1-11, 2014Tradução . . Disponível em: https://doi.org/10.1007/s12032-014-0851-5. Acesso em: 01 nov. 2024.
APA
Lima, L. T. de, Vivona, D., Bueno, C. T., Hirata, R. D. C., Hirata, M. H., Luchessi, A. D., et al. (2014). Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. Medical Oncology, 31, 1-11. doi:10.1007/s12032-014-0851-5
NLM
Lima LT de, Vivona D, Bueno CT, Hirata RDC, Hirata MH, Luchessi AD, Castro FA de, Chauffaille M de LLF, Zanichelli MA, Chiattone CS, Hungria VT de M, Guerra-Shinohara EM. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia [Internet]. Medical Oncology. 2014 ; 31 1-11.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1007/s12032-014-0851-5
Vancouver
Lima LT de, Vivona D, Bueno CT, Hirata RDC, Hirata MH, Luchessi AD, Castro FA de, Chauffaille M de LLF, Zanichelli MA, Chiattone CS, Hungria VT de M, Guerra-Shinohara EM. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia [Internet]. Medical Oncology. 2014 ; 31 1-11.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1007/s12032-014-0851-5
Trabalho de evento-resumo periodico
ABCB1 Haplotypes are associated with lower P-Gp activity and major molecular plasma levels in chronic myeloid leukemia patients (2013)
Vivona, Douglas; Lima, Luciene Terezinha de; Rodrigues, Alice Cristina ; Bueno, Carolina Tosin; Gaitani, Cristiane Masetto de; Chiattone, Carlos Sérgio; Hungria, Vania T; Chauffaille, Maria de Lourdes Lopes Ferrari; Guerra-Shinohara, Elvira Maria
Source: Blood. Conference titles: Annual Meeting and Exposition of the American Society of Hematology. Unidades: ICB, FCFRP, FCF
Assunto: LEUCEMIA MIELOIDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIVONA, Douglas et al. ABCB1 Haplotypes are associated with lower P-Gp activity and major molecular plasma levels in chronic myeloid leukemia patients. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. . Acesso em: 01 nov. 2024. , 2013
APA
Vivona, D., Lima, L. T. de, Rodrigues, A. C., Bueno, C. T., Gaitani, C. M. de, Chiattone, C. S., et al. (2013). ABCB1 Haplotypes are associated with lower P-Gp activity and major molecular plasma levels in chronic myeloid leukemia patients. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo.
NLM
Vivona D, Lima LT de, Rodrigues AC, Bueno CT, Gaitani CM de, Chiattone CS, Hungria VT, Chauffaille M de LLF, Guerra-Shinohara EM. ABCB1 Haplotypes are associated with lower P-Gp activity and major molecular plasma levels in chronic myeloid leukemia patients. Blood. 2013 ; 122( 21):[citado 2024 nov. 01 ]
Vancouver
Vivona D, Lima LT de, Rodrigues AC, Bueno CT, Gaitani CM de, Chiattone CS, Hungria VT, Chauffaille M de LLF, Guerra-Shinohara EM. ABCB1 Haplotypes are associated with lower P-Gp activity and major molecular plasma levels in chronic myeloid leukemia patients. Blood. 2013 ; 122( 21):[citado 2024 nov. 01 ]
Trabalho de evento-resumo periodico
ABCB1 haplotype is associated with alterations in functional activity of P-GP and affects major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib (2013)
Vivona, Douglas; Lima, L; Rodrigues, Alice Cristina ; Bueno, Carolina Tosin; Chauffaille, Maria de Lourdes Lopes Ferrari; Chiattone, Carlos Sérgio; Hungria, Vania Tietsche de Moraes; Guerra-Shinohara, Elvira Maria
Source: Haematologica. Conference titles: Congress of the European Hematology Association. Unidades: ICB, FCF
Subjects: LEUCEMIA MIELOIDE, POLIMORFISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIVONA, Douglas et al. ABCB1 haplotype is associated with alterations in functional activity of P-GP and affects major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Haematologica. Pavia: Instituto de Ciências Biomédicas, Universidade de São Paulo. . Acesso em: 01 nov. 2024. , 2013
APA
Vivona, D., Lima, L., Rodrigues, A. C., Bueno, C. T., Chauffaille, M. de L. L. F., Chiattone, C. S., et al. (2013). ABCB1 haplotype is associated with alterations in functional activity of P-GP and affects major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Haematologica. Pavia: Instituto de Ciências Biomédicas, Universidade de São Paulo.
NLM
Vivona D, Lima L, Rodrigues AC, Bueno CT, Chauffaille M de LLF, Chiattone CS, Hungria VT de M, Guerra-Shinohara EM. ABCB1 haplotype is associated with alterations in functional activity of P-GP and affects major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Haematologica. 2013 ; 98 404 res. P978.[citado 2024 nov. 01 ]
Vancouver
Vivona D, Lima L, Rodrigues AC, Bueno CT, Chauffaille M de LLF, Chiattone CS, Hungria VT de M, Guerra-Shinohara EM. ABCB1 haplotype is associated with alterations in functional activity of P-GP and affects major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Haematologica. 2013 ; 98 404 res. P978.[citado 2024 nov. 01 ]
Trabalho de evento-resumo
ABCB1 haplotypes are associated with lower P-Gp activity and major molecular response but do not affect imatinib plasma levels in chronic myeloid leukemia patients (2013)
Vivona, Douglas; Lima, Luciene Terezina de; Rodrigues, Alice Cristina ; Bueno, Carolina Tosin; Galtani, Cristiane M; Chiattone, Carlos Sérgio; Hungria, Vania Tietsche de Moraes; Chauffaille, Maria de Lourdes Lopes Ferrari; Guerra-Shinohara, Elvira Maria
Source: Abstracts. Conference titles: American Society of Hematology Annual Meeting and Exposition. Unidades: ICB, FCF
Subjects: LEUCEMIA MIELOIDE, POLIMORFISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIVONA, Douglas et al. ABCB1 haplotypes are associated with lower P-Gp activity and major molecular response but do not affect imatinib plasma levels in chronic myeloid leukemia patients. 2013, Anais.. Oxford: american Society of Hematology, 2013. . Acesso em: 01 nov. 2024.
APA
Vivona, D., Lima, L. T. de, Rodrigues, A. C., Bueno, C. T., Galtani, C. M., Chiattone, C. S., et al. (2013). ABCB1 haplotypes are associated with lower P-Gp activity and major molecular response but do not affect imatinib plasma levels in chronic myeloid leukemia patients. In Abstracts. Oxford: american Society of Hematology.
NLM
Vivona D, Lima LT de, Rodrigues AC, Bueno CT, Galtani CM, Chiattone CS, Hungria VT de M, Chauffaille M de LLF, Guerra-Shinohara EM. ABCB1 haplotypes are associated with lower P-Gp activity and major molecular response but do not affect imatinib plasma levels in chronic myeloid leukemia patients. Abstracts. 2013 ;[citado 2024 nov. 01 ]
Vancouver
Vivona D, Lima LT de, Rodrigues AC, Bueno CT, Galtani CM, Chiattone CS, Hungria VT de M, Chauffaille M de LLF, Guerra-Shinohara EM. ABCB1 haplotypes are associated with lower P-Gp activity and major molecular response but do not affect imatinib plasma levels in chronic myeloid leukemia patients. Abstracts. 2013 ;[citado 2024 nov. 01 ]
Trabalho de evento-resumo
Polymorphisms in ABC transporter genes are associated with complete molecular response to imatinib in chronic myeloid leukemia patients (2012)
Vivona, Douglas; Lima, Luciene Terezinha de; Bueno, Carolina Tosin; Hirata, Rosario Dominguez Crespo ; Hirata, Mario Hiroyuki ; Luchessi, André Ducati; Zanichelli, Maria Aparecida; Chiattone, Carlos Sérgio; Guerra-Shinohara, Elvira Maria
Source: Abstracts. Conference titles: Congress of the European Hematology Association. Unidade: FCF
Subjects: LEUCEMIA MIELOIDE, POLIMORFISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIVONA, Douglas et al. Polymorphisms in ABC transporter genes are associated with complete molecular response to imatinib in chronic myeloid leukemia patients. 2012, Anais.. The Hague: European Hematology Association, 2012. . Acesso em: 01 nov. 2024.
APA
Vivona, D., Lima, L. T. de, Bueno, C. T., Hirata, R. D. C., Hirata, M. H., Luchessi, A. D., et al. (2012). Polymorphisms in ABC transporter genes are associated with complete molecular response to imatinib in chronic myeloid leukemia patients. In Abstracts. The Hague: European Hematology Association.
NLM
Vivona D, Lima LT de, Bueno CT, Hirata RDC, Hirata MH, Luchessi AD, Zanichelli MA, Chiattone CS, Guerra-Shinohara EM. Polymorphisms in ABC transporter genes are associated with complete molecular response to imatinib in chronic myeloid leukemia patients. Abstracts. 2012 ;[citado 2024 nov. 01 ]
Vancouver
Vivona D, Lima LT de, Bueno CT, Hirata RDC, Hirata MH, Luchessi AD, Zanichelli MA, Chiattone CS, Guerra-Shinohara EM. Polymorphisms in ABC transporter genes are associated with complete molecular response to imatinib in chronic myeloid leukemia patients. Abstracts. 2012 ;[citado 2024 nov. 01 ]
Trabalho de evento-resumo
Efficacy and safety of deferasirox in patients with iron overload secondary to hereditary hemochromatosis: preliminary results of a 1-YR prospective study (2012)
Cançado, Rodolfo Delfini; Bastos, R; Melo, M; Santos, P; Guerra-Shinohara, Elvira Maria ; Chiattone, Carlos Sérgio
Source: Abstracts. Conference titles: Congress of the European Hematology Association. Unidade: FCF
Subjects: HEMOCROMATOSE, ANEMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CANÇADO, Rodolfo Delfini et al. Efficacy and safety of deferasirox in patients with iron overload secondary to hereditary hemochromatosis: preliminary results of a 1-YR prospective study. 2012, Anais.. The Hague: European Hematology Association, 2012. . Acesso em: 01 nov. 2024.
APA
Cançado, R. D., Bastos, R., Melo, M., Santos, P., Guerra-Shinohara, E. M., & Chiattone, C. S. (2012). Efficacy and safety of deferasirox in patients with iron overload secondary to hereditary hemochromatosis: preliminary results of a 1-YR prospective study. In Abstracts. The Hague: European Hematology Association.
NLM
Cançado RD, Bastos R, Melo M, Santos P, Guerra-Shinohara EM, Chiattone CS. Efficacy and safety of deferasirox in patients with iron overload secondary to hereditary hemochromatosis: preliminary results of a 1-YR prospective study. Abstracts. 2012 ;[citado 2024 nov. 01 ]
Vancouver
Cançado RD, Bastos R, Melo M, Santos P, Guerra-Shinohara EM, Chiattone CS. Efficacy and safety of deferasirox in patients with iron overload secondary to hereditary hemochromatosis: preliminary results of a 1-YR prospective study. Abstracts. 2012 ;[citado 2024 nov. 01 ]
Artigo de periodico
ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib (2012)
Vivona, Douglas; Bueno, Carolina Tosin; Lima, Luciene Terezinha de; Hirata, Rosario Dominguez Crespo ; Hirata, Mario Hiroyuki ; Luchessi, André Ducati; Zanichelli, Maria Aparecida; Chiattone, Carlos Sérgio; Guerra-Shinohara, Elvira Maria
Source: Blood Cells, Molecules, and Diseases. Unidade: FCF
Subjects: LEUCEMIA MIELOIDE AGUDA, POLIMORFISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIVONA, Douglas et al. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Blood Cells, Molecules, and Diseases, v. 48, n. 2, p. 132-136, 2012Tradução . . Disponível em: https://doi.org/10.1016/j.bcmd.2011.11.001. Acesso em: 01 nov. 2024.
APA
Vivona, D., Bueno, C. T., Lima, L. T. de, Hirata, R. D. C., Hirata, M. H., Luchessi, A. D., et al. (2012). ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Blood Cells, Molecules, and Diseases, 48( 2), 132-136. doi:10.1016/j.bcmd.2011.11.001
NLM
Vivona D, Bueno CT, Lima LT de, Hirata RDC, Hirata MH, Luchessi AD, Zanichelli MA, Chiattone CS, Guerra-Shinohara EM. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib [Internet]. Blood Cells, Molecules, and Diseases. 2012 ; 48( 2): 132-136.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.bcmd.2011.11.001
Vancouver
Vivona D, Bueno CT, Lima LT de, Hirata RDC, Hirata MH, Luchessi AD, Zanichelli MA, Chiattone CS, Guerra-Shinohara EM. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib [Internet]. Blood Cells, Molecules, and Diseases. 2012 ; 48( 2): 132-136.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.bcmd.2011.11.001
Trabalho de evento-resumo
SLC22A1 polymorphisms are not associated with cytogenetic and molecular response to imatinib mesylate in chronic myelogenous leukemia patients (2011)
Guerra-Shinohara, Elvira Maria ; Bueno, Carolina Tosin; Lima, Luciene Terezinha de; Vivona, Douglas; Hirata, Rosario Dominguez Crespo ; Hirata, Mario Hiroyuki ; Luchessi, André Ducati; Chiattone, Carlos Sérgio; Zanichelli, Maria Aparecida
Source: Abstracts. Conference titles: Annual Congress of the European Hematology Association (EHA). Unidade: FCF
Subjects: POLIMORFISMO, LEUCEMIA MIELOIDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GUERRA-SHINOHARA, Elvira Maria et al. SLC22A1 polymorphisms are not associated with cytogenetic and molecular response to imatinib mesylate in chronic myelogenous leukemia patients. 2011, Anais.. Hague: European Hematology Association (EHA), 2011. . Acesso em: 01 nov. 2024.
APA
Guerra-Shinohara, E. M., Bueno, C. T., Lima, L. T. de, Vivona, D., Hirata, R. D. C., Hirata, M. H., et al. (2011). SLC22A1 polymorphisms are not associated with cytogenetic and molecular response to imatinib mesylate in chronic myelogenous leukemia patients. In Abstracts. Hague: European Hematology Association (EHA).
NLM
Guerra-Shinohara EM, Bueno CT, Lima LT de, Vivona D, Hirata RDC, Hirata MH, Luchessi AD, Chiattone CS, Zanichelli MA. SLC22A1 polymorphisms are not associated with cytogenetic and molecular response to imatinib mesylate in chronic myelogenous leukemia patients. Abstracts. 2011 ;[citado 2024 nov. 01 ]
Vancouver
Guerra-Shinohara EM, Bueno CT, Lima LT de, Vivona D, Hirata RDC, Hirata MH, Luchessi AD, Chiattone CS, Zanichelli MA. SLC22A1 polymorphisms are not associated with cytogenetic and molecular response to imatinib mesylate in chronic myelogenous leukemia patients. Abstracts. 2011 ;[citado 2024 nov. 01 ]
Trabalho de evento-resumo
Haplotype for polymorphisms C1236T, C3435T and C2677T/A in MDR1 gene is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib (2011)
Guerra-Shinohara, Elvira Maria ; Vivona, Douglas; Bueno, Carolina Tosin; Lima, Luciene Terezinha de; Hirata, Rosario Dominguez Crespo ; Hirata, Mario Hiroyuki ; Luchessi, André Ducati; Zanichelli, Maria Aparecida; Chiattone, Carlos Sérgio
Source: Abstracts. Conference titles: Annual Congress of the European Hematology Association (EHA). Unidade: FCF
Subjects: POLIMORFISMO, LEUCEMIA MIELOIDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GUERRA-SHINOHARA, Elvira Maria et al. Haplotype for polymorphisms C1236T, C3435T and C2677T/A in MDR1 gene is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. 2011, Anais.. Hague: European Hematology Association (EHA), 2011. . Acesso em: 01 nov. 2024.
APA
Guerra-Shinohara, E. M., Vivona, D., Bueno, C. T., Lima, L. T. de, Hirata, R. D. C., Hirata, M. H., et al. (2011). Haplotype for polymorphisms C1236T, C3435T and C2677T/A in MDR1 gene is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. In Abstracts. Hague: European Hematology Association (EHA).
NLM
Guerra-Shinohara EM, Vivona D, Bueno CT, Lima LT de, Hirata RDC, Hirata MH, Luchessi AD, Zanichelli MA, Chiattone CS. Haplotype for polymorphisms C1236T, C3435T and C2677T/A in MDR1 gene is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Abstracts. 2011 ;[citado 2024 nov. 01 ]
Vancouver
Guerra-Shinohara EM, Vivona D, Bueno CT, Lima LT de, Hirata RDC, Hirata MH, Luchessi AD, Zanichelli MA, Chiattone CS. Haplotype for polymorphisms C1236T, C3435T and C2677T/A in MDR1 gene is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Abstracts. 2011 ;[citado 2024 nov. 01 ]
Trabalho de evento-resumo periodico
ABCG2 and SLC22A1 expression are associated with imatinib response in chronic myeloid leukemia (2011)
Vivona, Douglas; Lima, Luciene Terezina; Bueno, Carolina Tosin; Hirata, Rosario Dominguez Crespo ; Hirata, Mario Hiroyuki ; Luchessi, André Ducati; Zanichelli, Maria; Chiattone, Carlos Sérgio; Guerra-Shinohara, Elvira Maria
Source: Blood. Conference titles: Annual Meeting and Exposition of the American Society of Hematology (ASH). Unidade: FCF
Subjects: LEUCEMIA MIELOIDE, EXPRESSÃO GÊNICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIVONA, Douglas et al. ABCG2 and SLC22A1 expression are associated with imatinib response in chronic myeloid leukemia. Blood. Washington: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 01 nov. 2024. , 2011
APA
Vivona, D., Lima, L. T., Bueno, C. T., Hirata, R. D. C., Hirata, M. H., Luchessi, A. D., et al. (2011). ABCG2 and SLC22A1 expression are associated with imatinib response in chronic myeloid leukemia. Blood. Washington: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.
NLM
Vivona D, Lima LT, Bueno CT, Hirata RDC, Hirata MH, Luchessi AD, Zanichelli M, Chiattone CS, Guerra-Shinohara EM. ABCG2 and SLC22A1 expression are associated with imatinib response in chronic myeloid leukemia. Blood. 2011 ; 118( 21): 618 res. 604.[citado 2024 nov. 01 ]
Vancouver
Vivona D, Lima LT, Bueno CT, Hirata RDC, Hirata MH, Luchessi AD, Zanichelli M, Chiattone CS, Guerra-Shinohara EM. ABCG2 and SLC22A1 expression are associated with imatinib response in chronic myeloid leukemia. Blood. 2011 ; 118( 21): 618 res. 604.[citado 2024 nov. 01 ]
Artigo de periodico
Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients (2011)
Santos, Paulo Caleb Junior de Lima; Cançado, Rodolfo Delfini; Pereira, Alexandre C; Schettert, Isolmar Tadeu; Soares, Renata A. G; Pagliusi, Regina Alexandre; Hirata, Rosario Dominguez Crespo ; Hirata, Mario Hiroyuki ; Teixiera, Ana C; Figueiredo, Maria Stella; Chiattone, Carlos Sérgio; Krieger, José Eduardo; Guerra-Shinohara, Elvira Maria
Source: Blood Cells, Molecules, and Diseases. Unidades: FCF, FM
Subjects: HEMOCROMATOSE, SEQUENCIAMENTO GENÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS, Paulo Caleb Junior de Lima et al. Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients. Blood Cells, Molecules, and Diseases, v. 46, n. 4, p. 302-307, 2011Tradução . . Disponível em: https://doi.org/10.1016/j.bcmd.2011.02.008. Acesso em: 01 nov. 2024.
APA
Santos, P. C. J. de L., Cançado, R. D., Pereira, A. C., Schettert, I. T., Soares, R. A. G., Pagliusi, R. A., et al. (2011). Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients. Blood Cells, Molecules, and Diseases, 46( 4), 302-307. doi:10.1016/j.bcmd.2011.02.008
NLM
Santos PCJ de L, Cançado RD, Pereira AC, Schettert IT, Soares RAG, Pagliusi RA, Hirata RDC, Hirata MH, Teixiera AC, Figueiredo MS, Chiattone CS, Krieger JE, Guerra-Shinohara EM. Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients [Internet]. Blood Cells, Molecules, and Diseases. 2011 ; 46( 4): 302-307.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.bcmd.2011.02.008
Vancouver
Santos PCJ de L, Cançado RD, Pereira AC, Schettert IT, Soares RAG, Pagliusi RA, Hirata RDC, Hirata MH, Teixiera AC, Figueiredo MS, Chiattone CS, Krieger JE, Guerra-Shinohara EM. Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients [Internet]. Blood Cells, Molecules, and Diseases. 2011 ; 46( 4): 302-307.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.bcmd.2011.02.008
Trabalho de evento-resumo periodico
Imatinib response is influenced by ABCG2 and SLC22A1 gene expression in chronic myeloid leukemia (2011)
Lima, L. T; Vivona, Douglas; Bueno, C. T; Hirata, Rosario Dominguez Crespo ; Hirata, Mario Hiroyuki ; Luchessi, André Ducati; Zanichelli, Maria Aparecida; Chiattone, Carlos Sérgio; Guerra-Shinohara, Elvira Maria
Source: Revista Brasileira de Hematologia e Hemoterapia. Conference titles: Congresso Brasileiro de Hematologia e Hemoterapia. Unidade: FCF
Subjects: LEUCEMIA MIELOIDE AGUDA, EXPRESSÃO GÊNICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, L. T et al. Imatinib response is influenced by ABCG2 and SLC22A1 gene expression in chronic myeloid leukemia. Revista Brasileira de Hematologia e Hemoterapia. Rio de Janeiro: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 01 nov. 2024. , 2011
APA
Lima, L. T., Vivona, D., Bueno, C. T., Hirata, R. D. C., Hirata, M. H., Luchessi, A. D., et al. (2011). Imatinib response is influenced by ABCG2 and SLC22A1 gene expression in chronic myeloid leukemia. Revista Brasileira de Hematologia e Hemoterapia. Rio de Janeiro: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.
NLM
Lima LT, Vivona D, Bueno CT, Hirata RDC, Hirata MH, Luchessi AD, Zanichelli MA, Chiattone CS, Guerra-Shinohara EM. Imatinib response is influenced by ABCG2 and SLC22A1 gene expression in chronic myeloid leukemia. Revista Brasileira de Hematologia e Hemoterapia. 2011 ; 33 144-145 res. 0340.[citado 2024 nov. 01 ]
Vancouver
Lima LT, Vivona D, Bueno CT, Hirata RDC, Hirata MH, Luchessi AD, Zanichelli MA, Chiattone CS, Guerra-Shinohara EM. Imatinib response is influenced by ABCG2 and SLC22A1 gene expression in chronic myeloid leukemia. Revista Brasileira de Hematologia e Hemoterapia. 2011 ; 33 144-145 res. 0340.[citado 2024 nov. 01 ]
Trabalho de evento-resumo periodico
Frequency of C848T, C859G, C480G and A1222G polymorphisms in SLC22A1 gene in chronic myelogenous leukemia patients treated with imatinib mesilate (2011)
Bueno, Carolina Tosin; Lima, Luciene Terezinha de; Vivona, Douglas; Chiattone, Carlos Sérgio; Zanichelli, Maria Aparecida; Guerra-Shinohara, Elvira Maria
Source: Brazilian Journal of Pharmaceutical Sciences. Conference titles: Science and Pharmaceutical Technology Meeting of the Pharmaceutical Sciences Faculty of the University of São Paulo. Unidade: FCF
Assunto: POLIMORFISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BUENO, Carolina Tosin et al. Frequency of C848T, C859G, C480G and A1222G polymorphisms in SLC22A1 gene in chronic myelogenous leukemia patients treated with imatinib mesilate. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 01 nov. 2024. , 2011
APA
Bueno, C. T., Lima, L. T. de, Vivona, D., Chiattone, C. S., Zanichelli, M. A., & Guerra-Shinohara, E. M. (2011). Frequency of C848T, C859G, C480G and A1222G polymorphisms in SLC22A1 gene in chronic myelogenous leukemia patients treated with imatinib mesilate. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.
NLM
Bueno CT, Lima LT de, Vivona D, Chiattone CS, Zanichelli MA, Guerra-Shinohara EM. Frequency of C848T, C859G, C480G and A1222G polymorphisms in SLC22A1 gene in chronic myelogenous leukemia patients treated with imatinib mesilate. Brazilian Journal of Pharmaceutical Sciences. 2011 ; 47 44 res. FCF084.[citado 2024 nov. 01 ]
Vancouver
Bueno CT, Lima LT de, Vivona D, Chiattone CS, Zanichelli MA, Guerra-Shinohara EM. Frequency of C848T, C859G, C480G and A1222G polymorphisms in SLC22A1 gene in chronic myelogenous leukemia patients treated with imatinib mesilate. Brazilian Journal of Pharmaceutical Sciences. 2011 ; 47 44 res. FCF084.[citado 2024 nov. 01 ]
Trabalho de evento-resumo periodico
Polymorphisms in antitrombin (SERPINC1) and tissue factor pathway inhibitor (TFPI) genes are associated with recurrent pregnancy loss (2011)
Guerra-Shinohara, Elvira Maria ; Bertinato, Juliano Felix; Giusti, Kelma Cordeiro da Silva; Seino, Fernanda Midori; Bueno, Carolina Tosin; Carvalho, Mario Henrique Burlacchini de; Amorim Filho, Antônio Gomes; Zugaib, Marcelo; Chiattone, Carlos Sérgio
Source: Blood. Conference titles: Annual Meeting and Exposition of the American Society of Hematology (ASH). Unidades: FCF, FM
Assunto: POLIMORFISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GUERRA-SHINOHARA, Elvira Maria et al. Polymorphisms in antitrombin (SERPINC1) and tissue factor pathway inhibitor (TFPI) genes are associated with recurrent pregnancy loss. Blood. Washington: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 01 nov. 2024. , 2011
APA
Guerra-Shinohara, E. M., Bertinato, J. F., Giusti, K. C. da S., Seino, F. M., Bueno, C. T., Carvalho, M. H. B. de, et al. (2011). Polymorphisms in antitrombin (SERPINC1) and tissue factor pathway inhibitor (TFPI) genes are associated with recurrent pregnancy loss. Blood. Washington: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.
NLM
Guerra-Shinohara EM, Bertinato JF, Giusti KC da S, Seino FM, Bueno CT, Carvalho MHB de, Amorim Filho AG, Zugaib M, Chiattone CS. Polymorphisms in antitrombin (SERPINC1) and tissue factor pathway inhibitor (TFPI) genes are associated with recurrent pregnancy loss. Blood. 2011 ; 118( 21): 323-324 res. 331.[citado 2024 nov. 01 ]
Vancouver
Guerra-Shinohara EM, Bertinato JF, Giusti KC da S, Seino FM, Bueno CT, Carvalho MHB de, Amorim Filho AG, Zugaib M, Chiattone CS. Polymorphisms in antitrombin (SERPINC1) and tissue factor pathway inhibitor (TFPI) genes are associated with recurrent pregnancy loss. Blood. 2011 ; 118( 21): 323-324 res. 331.[citado 2024 nov. 01 ]
Trabalho de evento-resumo periodico
Polymorphisms in antitrombin (SERPINC1) and tissue factor pathway inhibitor (TFPI) genes are associated with recurrent pregnancy loss (2011)
Guerra-Shinohara, Elvira Maria ; Bertinato, Juliano Felix; Giusti, Kelma Cordeiro da Silva; Seino, Fernanda Midori; Bueno, Carolina Tosin; Carvalho, Mario Henrique Burlacchini de; Amorim Filho, Antônio Gomes; Zugaib, Marcelo; Chiattone, Carlos Sérgio
Source: Blood. Conference titles: American Society of Hematology (ASH). Unidades: FCF, FM
Subjects: POLIMORFISMO, ABORTO ESPONTÂNEO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GUERRA-SHINOHARA, Elvira Maria et al. Polymorphisms in antitrombin (SERPINC1) and tissue factor pathway inhibitor (TFPI) genes are associated with recurrent pregnancy loss. Blood. Washington: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 01 nov. 2024. , 2011
APA
Guerra-Shinohara, E. M., Bertinato, J. F., Giusti, K. C. da S., Seino, F. M., Bueno, C. T., Carvalho, M. H. B. de, et al. (2011). Polymorphisms in antitrombin (SERPINC1) and tissue factor pathway inhibitor (TFPI) genes are associated with recurrent pregnancy loss. Blood. Washington: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.
NLM
Guerra-Shinohara EM, Bertinato JF, Giusti KC da S, Seino FM, Bueno CT, Carvalho MHB de, Amorim Filho AG, Zugaib M, Chiattone CS. Polymorphisms in antitrombin (SERPINC1) and tissue factor pathway inhibitor (TFPI) genes are associated with recurrent pregnancy loss. Blood. 2011 ; 118( 21):[citado 2024 nov. 01 ]
Vancouver
Guerra-Shinohara EM, Bertinato JF, Giusti KC da S, Seino FM, Bueno CT, Carvalho MHB de, Amorim Filho AG, Zugaib M, Chiattone CS. Polymorphisms in antitrombin (SERPINC1) and tissue factor pathway inhibitor (TFPI) genes are associated with recurrent pregnancy loss. Blood. 2011 ; 118( 21):[citado 2024 nov. 01 ]
Trabalho de evento-resumo periodico
ABCG2 gene expression in chronic myeloid Leukemia patients treate with imatinib Mesylate (2011)
Lima, Luciene Terezinha de; Vivona, Douglas; Bueno, Carolina Tosin; Hirata, Rosario Dominguez Crespo ; Hirata, Mario Hiroyuki ; Chiattone, Carlos Sérgio; Zanichelli, Maria Aparecida; Guerra-Shinohara, Elvira Maria
Source: Brazilian Journal of Pharmaceutical Sciences. Conference titles: Science and Pharmaceutical Technology Meeting of the Pharmaceutical Sciences Faculty of the University of São Paulo. Unidade: FCF
Subjects: LEUCEMIA MIELOIDE AGUDA, EXPRESSÃO GÊNICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Luciene Terezinha de et al. ABCG2 gene expression in chronic myeloid Leukemia patients treate with imatinib Mesylate. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 01 nov. 2024. , 2011
APA
Lima, L. T. de, Vivona, D., Bueno, C. T., Hirata, R. D. C., Hirata, M. H., Chiattone, C. S., et al. (2011). ABCG2 gene expression in chronic myeloid Leukemia patients treate with imatinib Mesylate. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.
NLM
Lima LT de, Vivona D, Bueno CT, Hirata RDC, Hirata MH, Chiattone CS, Zanichelli MA, Guerra-Shinohara EM. ABCG2 gene expression in chronic myeloid Leukemia patients treate with imatinib Mesylate. Brazilian Journal of Pharmaceutical Sciences. 2011 ; 47 66 res. FCF128.[citado 2024 nov. 01 ]
Vancouver
Lima LT de, Vivona D, Bueno CT, Hirata RDC, Hirata MH, Chiattone CS, Zanichelli MA, Guerra-Shinohara EM. ABCG2 gene expression in chronic myeloid Leukemia patients treate with imatinib Mesylate. Brazilian Journal of Pharmaceutical Sciences. 2011 ; 47 66 res. FCF128.[citado 2024 nov. 01 ]

USP Schools

ReP

Filtros

USP Schools

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Conference titles

Countries/Territories

Funding Agencies

Indexado em

Normalized affiliation

Non normalized affiliation